<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04881578</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00016</org_study_id>
    <nct_id>NCT04881578</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study</brief_title>
  <acronym>ALFA ROMEO</acronym>
  <official_title>Atrial Fibrillation Before and After Patent Foramen Ovale Closure Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raban Jeger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the ALFA ROMEO study is to better understand the association between cryptogenic&#xD;
      stroke, PFO, PFO closure and AF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients with cryptogenic stroke and PFO, a better understanding of the exact incidence&#xD;
      of new-onset AF before and after PFO closure, its occurrence during follow-up, its&#xD;
      persistence or reversibility and its prognostic impact is critical: If only a PFO, but no AF&#xD;
      is available, then PFO closure followed by a limited duration of antiplatelet therapy is&#xD;
      indicated. If on the other hand side a PFO and AF is found, lifelong therapeutic&#xD;
      anticoagulation is mandatory.&#xD;
&#xD;
      By using the contemporary ICM protocols to search for silent AF in patients with cryptogenic&#xD;
      stroke and a PFO for 3 months before PFO closure, ALFA ROMEO will help to understand the&#xD;
      relationship of silent and previously undetected AF in the setting of PFO and investigate the&#xD;
      true incidence of new-onset AF and its temporal course after effective PFO closure. Our&#xD;
      findings will have the potential to impact on the future diagnostic and therapeutic&#xD;
      management of patients with cryptogenic stroke and a PFO&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of first AF within 12 months after percutaneous PFO occlusion</measure>
    <time_frame>12 months</time_frame>
    <description>to assess the incidence of first AF within 12 months after percutaneous PFO closure with a prespecified landmark analysis after 3 months to differentiate potentially device related AF (months 0-3) from likely intrinsic AF (months 4-12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of first AF within 3 months of continuous rhythm monitoring before the intended percutaneous PFO closure procedure</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall incidence of first AF from ICM-implantation to ICM-explantation or 36 months post implantation (if ICM remains in situ) excluding a blanking period of the first 3 months after PFO closure</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the primary endpoint according to the grade of the PFO</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of recurrent clinical embolic events such as cryptogenic strokes or systemic embolism including pulmonary embolism (with the use of the TOAST classification algorithm)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF burden, defined as proportion of follow-up time with documented AF at different time points</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of major bleeding (BARC 3 to 5)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of any death and cardiovascular death at different timepoints</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device related events</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cryptogenic Stroke</condition>
  <condition>Foramen Ovale, Patent</condition>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>continuous cardiac monitoring before and after transcatheter PFO closure</intervention_name>
    <description>Data will be assessed from patients with cryptogenic stroke and planned PFO occlusion who undergo the contemporary ICM protocols to search for silent AF</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with a history of systemic embolization, i.e., cryptogenic stroke or acute&#xD;
        peripheral arterial closures, and a concomitant PFO&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of embolic events such as cryptogenic stroke or systemic embolism (single&#xD;
             event or multiple events). A stroke is considered to be cryptogenic if no possible&#xD;
             cause can be determined despite extensive workup according to the standard protocol of&#xD;
             the participating center (TOAST classification 5b) (29). Before inclusion in the&#xD;
             study, the following tests are required as standard tests to establish the diagnosis&#xD;
             of cryptogenic stroke:&#xD;
&#xD;
               -  MRI or computed tomography (CT) of the neurocranium (documenting ischemic embolic&#xD;
                  stroke)&#xD;
&#xD;
               -  12-lead ECG (exclusion of AF)&#xD;
&#xD;
               -  Continuous ECG monitoring for at least 7 days (inpatient telemetry or Holter-ECG&#xD;
                  as an in- or outpatient&#xD;
&#xD;
               -  Ultrasonography, CT or MRI angiography of head and neck to rule out arterial&#xD;
                  disease as a cause of stroke (see below), or other potential causes of stroke&#xD;
&#xD;
          2. Cardiac monitoring is planned to be performed with the BIOMONITOR III(m) device&#xD;
&#xD;
          3. Presence of right-to-left shunt through a PFO as assessed by means of transesophageal&#xD;
             echocardiography (TEE) with agitated saline while the patient is at rest or while a&#xD;
             Valsalva maneuver is being performed.&#xD;
&#xD;
          4. Occlusion of PFO is planned to be performed with the AMPLATZERTM PFO OCCLUDER device.&#xD;
&#xD;
          5. Patient is willing to sign patient consent form.&#xD;
&#xD;
          6. Age ≥18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known etiology of the embolic event (based on neuro-/cardiac/vascular imaging), such&#xD;
             as:&#xD;
&#xD;
               -  Evidence of large-artery atherosclerosis (ultrasonography, CT or MRI angiography,&#xD;
                  or digital subtraction angiography) with stenosis of 50% or more in the artery&#xD;
                  feeding the acute ischemic territory.&#xD;
&#xD;
               -  Small vessel disease, defined by radiographic appearance consistent with ischemic&#xD;
                  infarction in the territory of a perforating arteriole, with ≤20 mm in diameter&#xD;
                  on axial sections and not involving the cortex, located in the white matter,&#xD;
                  internal or external capsule, deep brain nuclei, thalamus, or brainstem.&#xD;
&#xD;
               -  Evidence of a high-risk cardiac or aortic arch source of embolism (left&#xD;
                  ventricular or left atrial thrombus or &quot;smoke,&quot; emboligenic valvular lesion or&#xD;
                  tumor, aortic arch plaque &gt;3 mm thick or with mobile components or any other&#xD;
                  high-risk lesion)&#xD;
&#xD;
               -  Stroke of other determined cause such as presence of non-atherosclerotic&#xD;
                  vasculopathies (i.e. dissection, fibromuscular dysplasia), hypercoagulable states&#xD;
                  (must be tested in patients &lt;55 years old) and hematologic disorders&#xD;
&#xD;
          2. Atrial septal defect or ventricular septal defect.&#xD;
&#xD;
          3. Coronary or valvular disease requiring surgical intervention.&#xD;
&#xD;
          4. Documented history of AF or atrial flutter.&#xD;
&#xD;
          5. Permanent indication for therapeutic oral anticoagulation at enrollment.&#xD;
&#xD;
          6. Already included in another clinical trial that will affect the objectives of this&#xD;
             study.&#xD;
&#xD;
          7. Life expectancy &lt;1 year.&#xD;
&#xD;
          8. Pregnancy.&#xD;
&#xD;
          9. Patient underwent or is scheduled for implantation of a pacemaker, implantable&#xD;
             cardioverter defibrillator or cardiac resynchronization therapy device.&#xD;
&#xD;
         10. Unable or unwilling to follow the required procedures of the Clinical Investigation&#xD;
             Plan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raban Jeger, Prof Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Reichlin, Prof Dr med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bern Inselspital, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raban Jeger, Prof Dr med</last_name>
    <phone>+41 61 265 25 25</phone>
    <email>raban.jeger@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicole Gilgen, Dr med</last_name>
    <phone>+41 61 265 25 25</phone>
    <email>nicole.gilgen@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cantonal Hospital Aarau Cardiology</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miriam Brinkert, Dr med</last_name>
      <phone>+41 62 838 41 41</phone>
      <email>miriam.brinkert@ksa.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel, Heart Center</name>
      <address>
        <city>Basel</city>
        <zip>4053</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raban Jeger, Prof Dr med</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>raban.jeger@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Gilgen, Dr med</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>nicole.gilgen@usb.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital Bern Inselspital Cardiology</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Reichlin, Prof Dr med</last_name>
      <phone>+41 31 632 21 11</phone>
      <email>tobias.reichlin@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bürgerspital Solothurn Cardiology</name>
      <address>
        <city>Solothurn</city>
        <zip>4500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Vogel, Prof Dr med et phil nat</last_name>
      <phone>+41 32 627 31 21</phone>
      <email>Rolf.Vogel@spital.so.ch</email>
    </contact>
    <investigator>
      <last_name>Tilmann Perrin, Dr med</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital St.Gallen Cardiology</name>
      <address>
        <city>St.gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Weilenmann, Dr med</last_name>
      <phone>+41 71 494 11 11</phone>
      <email>Daniel.Weilenmann@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Zürich Cardiology</name>
      <address>
        <city>Zürich</city>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Breitenstein, PD Dr med</last_name>
      <phone>141 44 255 11 11</phone>
      <email>Alexander.Breitenstein@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Basel, Switzerland</investigator_affiliation>
    <investigator_full_name>Raban Jeger</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>occlusion of patent foramen ovale</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

